ADDEX THERAPEUTICS LTD
ADXNNASDAQTrading Snapshot
- Day Range
- $2.88 – $3.01
- 52-Week Range
- $2.56 – $10.43
- Volume (shares)
- 7,139
- Avg Volume (shares)
- —
- Shares Outstanding
- 1.2M
- Next Earnings
- 2026-11-09
Fundamentals Snapshot
- Annual Revenue
- $29,972
- Last Q Revenue
- $9,908
- P/E Ratio
- -0.4
- P/S Ratio
- 42.3x
- EPS (TTM)
- $-4.73
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +45.5%
ADDEX THERAPEUTICS LTD
ADXN
StockOtter · stockotter.spaceAbout ADDEX THERAPEUTICS LTD
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Reviewing Addex Therapeutics (NASDAQ:ADXN) & Clene (NASDAQ:CLNN)
Clene (NASDAQ: CLNN - Get Free Report) and Addex Therapeutics (NASDAQ: ADXN - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the
Addex (NASDAQ: ADXN) spin-out Neurosterix clears Phase 1, plans next stage
What happened Addex Therapeutics Ltd. (NASDAQ: ADXN) said Neurosterix completed Phase 1 studies of NTX-253 and plans to move the drug into Phase 2. NTX-253 is a positive allosteric modulator of the muscarinic M4 receptor
Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel sm
Addex Therapeutics Announces Executive Management Changes
Jean-Philippe Rocher Appointed Head of Pharmaceutical Development Mikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 2, 2026 - Addex Ther
What Addex Therapeutics (ADXN) Said on Its Q2 Earnings Call
Addex Therapeutics (NASDAQ: ADXN) reported a CHF 1.1 million operating loss for the first half of 2026, compared with CHF 1.3 million a year earlier, as reduced outsourced research and development spending on its GABAB p
Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript
Addex Therapeutics Ltd (ADXN) Q2 2026 Earnings Call Transcript